Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4085 - Postoperative Radiation Therapy After Radical Prostatectomy


10 Sep 2017


Poster display session


Surgical Oncology;  Radiation Oncology;  Prostate Cancer


Asuncion del Carmen Hervas Moron


Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370


A.D.C. Hervas Moron, C. Vallejo, J. Domínguez, F. López, M. Martin, D. Candini, E. Carrasco, S. Sancho

Author affiliations

  • Radiation Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES


Abstract 4085


To analize the results of adjuvant and salvage radiotherapy after radical prostatectomy and to determine prognostic factors of biochemical relapse free survival (BRFS).


302 patients were treated at our institution over a 12-year period. Overall survival and biochemical-relapse free survival were calculated using Kaplan-Meier and multivariate Cox regression analysis was used to assess differences between groups.


Mean age at diagnosis was 65 years (42-80). All patients underwent radical prostatectomy combined with pelvic lymphadenectomy in 47.1% of cases. Adjuvant RT was performed in 113 patients and salvage RT in 183 (9 for local recurrence). The distribution of patients by pT stage was pT2a-b(30.3%), pT2c (35%), pT3(29%) and pT4(2.3%). Upgrade in Gleason score between biopsy and prostatectomy was experienced by 46.7% of patients. Positive surgical margins were reported in 56.5% of cases. Neoadjuvant androgen ablation before surgery was given to 36.5%. Mean pre-RT PSA of 0.46ng/ml (0-12.8) and mean dosis to surgical bed was of 70Gy (60-76Gy). Mean follow-up was 58.85 months (1-153 months). Overall survival at 5 and 10 years was 98.1% and 94.3%, respectively and BRFS at 5 and 10 years was 76.5% vs. 61.8%, respectively. The timing of RT (ART vs. SRT) and pre-RT PSA


Postoperative radiation therapy provides excellent long-term overall survival with an aceptable BRFS. Pre-RT PSA

Clinical trial identification

Legal entity responsible for the study

Hospital Ramón y Cajal




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.